Label comprehension guidance on list again
This article was originally published in The Tan Sheet
Executive SummaryThe Center for Drug Evaluation and Research continues developing its guidance on label comprehension studies for nonprescription drugs. The center Feb. 5 publishes its 2009 1agenda of guidances, a list that includes a total of 42 items in 14 CDER categories. Specifically, the list includes guidances on labeling dietary supplements for women who are or could be pregnant, dosage delivery devices for liquid OTCs and drug names and dosage forms. Publication of the guidance on label comprehension studies is anticipated by drug firms because questions on the design of such studies surfaced during FDA advisory committees' reviews of Rx-to-OTC switch applications (2"The Tan Sheet" Sept. 22, 2008, p. 6). CDER long has recommended improving OTC labeling and label comprehension studies to account for the growing complexity of nonprescription drugs and their indications (3"The Tan Sheet" Dec. 4, 2006, p. 9)
You may also be interested in...
MDSAP And USMCA: 3 Ways Mexico Can To Come Up-To-Speed With The Single-Audit Program Targeted By New Free-Trade Accord
The US-Mexico-Canada (USMCA) treaty calls for the three countries to “recognize audits” performed under the Medical Device Single Audit Program. MDSAP is already used by device makers in the US and Canada so they can undergo one audit by an accredited third party to satisfy quality regulations. That leaves Mexico as the odd country out when it comes to using the popular program – and that means it has some catching up to do after the USMCA is ratified by all three nations. Former longtime FDA official Kim Trautman weighs in on how Mexico can incorporate MDSAP into its regulatory framework.